New antibiotic combo tested in healthy volunteers
NCT ID NCT06665555
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study tested how two antibiotics, ceftibuten and ledaborbactam, move through the blood and lungs of 34 healthy adults aged 18-55. Participants took five doses of the drugs and underwent a bronchoscopy to measure drug levels in lung fluid. The goal was to understand safety and drug distribution, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ceftibuten and ledaborbactam etzadroxil
- What this could lead to
- If successful, this could help determine the right doses for future studies of this antibiotic combination against lung infections.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not patients. It only measures drug levels, not whether the drug works against infections. Results may not predict real-world effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pulmonary Associates
Phoenix, Arizona, 85032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Can a simple calcium tablet help prevent postpartum bleeding?
- Brain waves under pressure: can light uncover the signature of mental work?